
GUIDANCE MATERIAL

Gavi Vaccine Budget Simulation Tool

VFSM November 2026

gavi.org

The Role of the Vaccine Budget Simulation Tool in Gavi 6.0 Ecosystem



Resources

Vaccine Budget Policy (TBC)

Gavi Detail Product Profile

UNICEF Vaccine Pricing Data

WHO Vaccine Position Papers

VB Simulation Tool Excel

VB Simulation Tool User Guide

VB Simulation Tool Trainings/Recordings

VPOP Toolkit

Gavi Funding Guidelines

Country Vaccine Dose Plan




1

VB Simulation Tool Conceptual Overview

Vaccine Budget Simulation Tool

A Decision-Support Tool for Vaccine Budget Alignment



Model and compare scenarios
The **VB Simulation Excel Tool** enables countries to model and compare vaccine programme **scenarios** against the Vaccine Budget (VB).

Estimate budget implications
The tool supports planning and decision-making by estimating vaccine volumes, programme costs, financing requirements, and budget implications for **Gavi-supported vaccine programmes.**

Submit the preferred scenario
Countries will submit their preferred scenario as **the vaccine dose plan**, together with supporting narrative and any stand-by activities documented in **Annex F.**

Key Inputs and Usage Considerations

Category	Elements
Data Sources & Assumptions	• The Vaccine Budgets (VB) reflect the amounts communicated in the Gavi Country Letters of **August 2026** • The prepopulated scenario combines issued or imminent **Gavi Decision Letter data (2026–2027)** and Gavi projected programmatic volumes for 2028-2030. • Costs are calculated using **Q1 2026 unloaded public price*** forecasts and freight assumptions and are subject to change.
Limitations and Updates	• Current version: **17 September 2026**. Future updates will be shared periodically, with planned integration into Gavi's **Grants Management System (GMS)** • All data presented in the tool is **indicative** and intended for scenario generation purposes only
Country Applications	• Countries will submit their preferred scenario as the vaccine dose plan, together with supporting narrative and stand-by options in **Annex F** • Final allocations will be confirmed in the official **Gavi Decision Letter** after approval of the Country Application

*Price (USD) includes only the vaccine dose; associated costs (freight, cold chain, administration, wastage) are excluded. Where multiple suppliers or price ranges exist, a weighted average price (WAP) is used.

Gavi
The Vaccine Alliance

Understanding Inputs, Parameters, Assumptions, and Scenarios

TERM	WHAT IT MEANS	HOW IT'S USED	EXAMPLES
Scenario	A planning case of country choices on programming and parameters.	Simulates volumes, costs, financing needs and budget impact.	Introduction timing; switch products; Stand-By List activities.
Parameters	Inputs users can change within a scenario.	Tests alternative programming choices.	Programme, timing, doses, population, scale, coverage and wastage.
Assumptions	Baseline conditions applied by the model.	Sets the data and rules for calculations and projections.	Demand forecasts, prices, co-financing and policy.
Outputs	Results generated from the selected parameters and assumptions.	Supports comparison and decision-making.	Volumes, costs, budget variance and financing split.

Vaccine Budget Simulation Tool: Set-up Requirements



Desktop

- Ensure you have Microsoft 365 or Microsoft Excel 2021 or later
- The tool must be used in the desktop version of Excel; functionality may be limited in Excel Online or browser-based environments
- Save and work from a local copy of the file to ensure stability and full functionality.



Enable Macros

- Users should click “Enable Content” when opening the file.
- File → Options → Trust Center → Trust Center Settings → Macro Settings → Disable VBA macros with notification → OK
- If macros are disabled, key functions (e.g., recalculation, reset, and export features) will not operate as intended.



Tool Modification

- Peach coloured cells highlight modifiable cells for user input
- Blue coloured cells indicate auto-calculating fields
- Avoid modifying protected or formula cells.
- To perform your own analysis, export the dataset as an xlsx or csv file




2

Tool Layout & Scenario Generation

Tool Layout: Gavi Vaccine Budget Menu

The VB Simulation Tool has a customize menu in the Excel ribbon


Custom Menu



Tool Layout: Collapsed View

The VB Simulation Tool is organized into seven sections

Header Bar



SUMMARY DASHBOARD

- Snapshot Dashboard

USER INPUT SECTIONS (Modifiable)

- Programme & Product
- Volume Calibration

SUMMARY SECTIONS


- Cost Summary & Annual Breakdown
- Decision Letter & Disbursements

REFERENCE

- Vaccine Price Reference

Header Bar

Use the header bar as an orientation check: confirm context, scan alerts, and review budget position.



Review Input Sections: Programme-Product Selection and Volume Calculations to resolve errors


Understand budget position and interpret surplus (green) and deficits (red) between Effective Budget and Scenario Cost

Understand the scenario position and cost split between Gavi and Country


Gavi The Vaccine Alliance

Error Notifications

Notification boxes signal; tool errors or readiness to recalculate and the budget position




Input Required
No scenario data available




Within Budget
Scenario is aligned with the available Vaccine Budget

All required inputs have been completed; the scenario can be recalculated



Scenario Unbalanced
Either Guaranteed or Discretionary Budget is in deficit



One or more required inputs are missing or invalid; corrections are needed before recalculation

Over Budget
Scenario cost exceeds the available Vaccine Budget

Where a scenario exceeds the available Vaccine Budget, the **"Validate Budget"** function provides guidance on potential adjustments to address identified funding gaps.

Scenario Snapshot Dashboard: Budget Overview

Budget tables display calculations and changes impacting the Effective Budget

6.0 Guaranteed Budget

Initial Vaccine Budget		Self-Financed Guaranteed Programs		Budget Transfer from Discretionary	=	Effective Budget	Total Gavi Scenario Cost		Budget Remaining	Standby (Gavi Component)
$ 36.50 M		$ 13.44 M		$ 5.60 M		$ 28.66 M	$ 28.64 M		$ 0.03 M	
		37%		15%		79%			0%	

6.0 Discretionary Budget

Initial Vaccine Budget		Self-Financed Guaranteed Programs		Budget Transfer to Guaranteed	=	Effective Budget	Total Gavi Scenario Cost	Self-Financed Discretionary Programs	Budget Remaining	Standby (Gavi Component)
$ 12.54 M		$ 13.44 M		$ 5.60 M		$ 20.38 M	$ 15.12 M	$ 4.72 M	$ 5.27 M	
		107%		45%		162%		38%	26%	

Guaranteed Budget Remaining	$ 0.03 M	Within Budget
Budget to Transfer From Discretionary To Guaranteed		$ 5.60 M
Discretionary Budget Remaining	$ 5.27 M	Within Budget

Self-financing guaranteed programmes frees up funds for discretionary use

Discretionary budget surpluses can be used to supplement guaranteed programmes

Users can determine the amount of discretionary surplus to transfer to guaranteed programmes

Gavi The Vaccine Alliance

Scenario Snapshot Dashboard: Programme & Cost Overview

The Snapshot update automatically from recalculations of user-modifiable inputs

6.0 Guaranteed Budget

Initial Vaccine Budget	− Self-Financed Guaranteed Programs	+ Budget Transfer from Discretionary	= Effective Budget	Total Gavi Scenario Cost	Budget Remaining	Standby (Gavi Component)
	100%					

Guaranteed Programs

Vaccine	Program	Support Policy	In Scenario?	Standby	Gavi Cost	Co-Financing Cost	Self-Financing Cost	New / Existing	Year of Intro | Switch
Hexa	Routine	Standard	Yes		$ 23.33 M			New	2028 | NA
HPV	Routine	Standard	Yes		$ 7.25 M			New	2026 | 2028
IPV	Routine	Standard	Yes		$ 7.06 M			New	2026 | NA
MR	FU Campaign	Standard	Yes		$ 4.01 M			New	2027 | NA
PCV	Routine	Standard	Yes		$ 36.06 M			New	2026 | 2029
Pentavalent	Routine	Standard	Yes		$ 6.03 M			New	2026 | NA
Rota	Routine	Standard	Yes		$ 13.78 M			New	2026 | NA
Total									

6.0 Discretionary Budget

Initial Vaccine Budget	+ Self-Financed Guaranteed Programs	− Budget Transfer to Guaranteed	= Effective Budget	Total Gavi Scenario Cost	Self-Financed Discretionary Programs	Budget Remaining	Standby (Gavi Component)
	100%					100%	

Discretionary Programs

Vaccine	Program	Support Policy	In Scenario?	Standby	Gavi Cost	Co-Financing Cost	Self-Financing Cost	New / Existing	Year of Intro | Switch
Malaria	Routine	Standard	Yes		$ 43.29 M			New	2026 | NA
MenA	Routine	Standard	Yes		$ 1.80 M			New	2026 | NA
MMCV	Routine	Standard	Yes		$ 10.81 M			New	2028 | NA
TCV	Routine	Standard	Yes		$ 5.41 M			New	2026 | NA
Total									

A “Yes” or “No” indicator shows whether a programme is included and costed in the scenario

Gavi The Vaccine Alliance

Scenario Design: Vaccine Programming & Product Selection

Define vaccine programmes and product choice including switch timing

Programme Selection

Vaccine Programme Selection.
Default is Standard; with option for F&H

Presentation Choice

Drop down selection of
Existing or Switch Product

User Input: Programs

6.0 Program and Presentation Selection

					Funding Type							Switch Table				
6.0 Co-Financing Eligibility Group					ISF	ISF	ISF	PT	PT			ISF	ISF	ISF	PT	PT
Vaccine	Program	Support	Budget Cat.	New / Existing	2026	2027	2028	2029	2030	Main Presentation (P1)	Switch Presentation (P2)	2026	2027	2028	2029	2030
Rota	Routine	Standard	Guaranteed	Existing	Gavi	Gavi	Gavi	Gavi	Gavi	Rotavac RV1, 10 doses/vial, frozen	Rotavac RV1, 5 doses/vial, frozen	P1	P1	P1	P2	P2

Years of Support

- Gavi Support
- Self-Financed
- Stand-by

Switch Timing

P1: Existing or New Introduction Product
P2: Switch Product

Gavi The Vaccine Alliance


Scenario Design: Vaccine Programming & Volume Calibration

Input first-principle configurations (population, coverage, and wastage) to calculate volumes

2026/27 Decision Letters Greyed out

Table Header autofills from Vaccine Programming section

Annual summary graphs support quick visualisation of volume & cost



Year	Vaccine Presentation	Decision Letter Issued	Program Scale Factor	Start Date (default 1 Jan)	Doses in Schedule	Population	Coverage - First Dose	Coverage - Second Dose	Coverage - Third Dose	Coverage - Fourth Dose	Coverage - Fifth Dose	Wastage Rate	Buffer Policy	Vaccine Need with Wastage	Incremental Buffer	Volume Adjustment	Vaccine Volume	Device Volume
2026	IPV, 5 dose/vial, liquid		100%	01 Jan 2026	2	898,907	94%	91%				7%	25%	1,788,148	447,037		2,235,800	2,258,175
2027	IPV, 5 dose/vial, liquid		100%	01 Jan 2027	2	905,086	95%	92%				7%	25%	1,813,287	6,285		1,820,000	1,838,200

Auto populating Columns

Year, Vaccine Product & Existing Decision Letter Auto populate

Input Fields

User input: Scale Factor; Start Date; Doses in Schedule; Population; Coverage & Wastage Rate

Volume Calculations


Vaccine & Devices volumes auto calculate

16 Please note that the buffer policy (previously defaulted to 25%) is now configurable. However, volume adjustments for 2026 and 2027 have been retained to align with issued or imminent Decision Letters.

Gavi The Vaccine Alliance

Summary: Annual Scenario Volumes & Costs

Volume and Cost Tables by Vaccine Programme



Volume & Cost Tables

1. Total: Gavi + Country
2. Gavi only
3. Cofinancing
4. Self-financing

Programme Totals

Total Volume and Cost Columns for the full 6.0 Strategic Period

Decision Letter Volume & Cost

2026/27 Decision Letter Volumes and Costs highlighted in purple

Programme-Year Splits

Volume and Cost Split for each year of the 6.0 Strategic Period

Gavi The Vaccine Alliance

Summary: Decision Letters & Disbursement To Date

Decision Letters Issued & Imminent, 2026-2027

Decision Letter costs and disbursements split by Guaranteed/Discretionary for 2026/27

Decision Letters and Disbursements To Date

2026 Guaranteed Programs		
Scenario Cost	Decision Letter	Disbursed
% of Cost:	100%	50%

2027 Guaranteed Programs		
Scenario Cost	Decision Letter	Disbursed
% of Cost:		

2026 Discretionary Programs		
Scenario Cost	Decision Letter	Disbursed
% of Cost:		

2027 Discretionary Programs		
Scenario Cost	Decision Letter	Disbursed
% of Cost:		

Gavi Costs in Scenario, Decision Letters, and Disbursements to Date

						5.1 in 6.0	2026						2027					
Vaccine	Program	Support Policy	Category	New/Existing	In Scenario	Disbursed	Scenario Cost	Cost on DL	% of Cost	Disbursed	% of DL		Scenario Cost	Cost on DL	% of Cost	Disbursed	% of DL	
HPV	Routine	Standard	Guaranteed	Existing	Yes		$0.36 M	$0.36 M	100%	$0.37 M	103%		$0.56 M					
IPV	Routine	Standard	Guaranteed	Existing	Yes	$0.03 M	$0.96 M	$0.96 M	100%	$0.52 M	54%							
MR	FU Campaign	Standard	Guaranteed	Existing	Yes		$0.82 M	$0.82 M	100%									
PCV	Routine	Standard	Guaranteed	Existing	Yes		$1.93 M	$1.93 M	100%	$0.97 M								

Scenario Cost $

Amount of issued DL costed against the 6.0 Vaccine Budget

Cost & Disbursed ($ and %)

$ costs and disbursements are displayed alongside proportional bar charts for easy comparison

Gavi The Vaccine Alliance

6.0 Unloaded Vaccine Price Forecast

Vaccine & Devices prices by year as per Q1 2026 projections

Reference

6.0 Vaccine Price Forecast (Unloaded Prices)

Vaccine	Presentation	2026	2027	2028	2029
Cholera	OCV	$1.53	$1.53	$1.53	$1.53
Device	Safety Box	$0.86	$0.86	$0.86	$0.86
Device	Syringe, A-D 0.1ml	$0.05	$0.05	$0.05	$0.05
Device	Syringe, A-D 0.2ml	$0.05	$0.05	$0.05	$0.05
Device	Syringe, A-D 0.5ml	$0.04	$0.04	$0.04	$0.04
Device	Syringe, A-D 1.0ml	$0.04	$0.04	$0.04	$0.04
Device	Syringe, RUP 2, Generic	$0.06	$0.06	$0.06	$0.06
Device	Syringe, RUP 5, Generic	$0.06	$0.06	$0.06	$0.06
DTPB1	DTP VACCINE, ADSORBED, 10 DOSE VIAL	$0.29	$0.29	$0.29	$0.29
DTPB2	Td, 10 doses/vial, liquid		$0.14	$0.14	$0.14
DTPB3	Td, 10 doses/vial, liquid		$0.14	$0.14	$0.14
HepB	HepB Pediatric, 10 dose/vial	$0.24	$0.24	$0.24	$0.24
Hexa	HEXA, 10 DOSE/VIAL, LIQUID	$2.85	$2.85	$2.60	$2.20
HPV	HPV CVB Budgeting Price	$2.90	$2.90	$2.90	$2.90

RSV 3 doses/vial, liquid:
enter indicative unloaded price per dose ($) if received from Gavi Senior Country Manager

2028	
2029	
2030	

RSV Unloaded Price

Manually enter the SCM-provided RSV price from the introduction year onward

Vaccine & Devices Prices

Projected unloaded vaccine prices for the strategic period

📖 Notes: Read me

Important Notes on Presentations and Pricing

Listed prices for all presentations reflect current price expectations as of Q1 2026 and are subject to change. Please contact your Gavi Senior Country Manager for further details. Countries should also refer to UNICEF website for latest prices: https://www.unicef.org/supply/vaccines-pricing-data

Important information for Penta/IPV/Hexa: Hexavalent (Hexa) prices for 2028–2030 assume price parity under an ambitious demand scenario via UNICEF tenders. If Hexa prices are higher than expected, programme switches may need to be delayed to remain within the 6.0 budget. Penta/IPV prices may be higher than currently indicated.

Important information for Malaria: Countries currently using Malaria RTS,S vaccine will see a 'VB budget price' under the 'Switch Presentation' column if using the VB forecast assumptions. This does not represent a switch of vaccines; Gavi will procure the current in-country product, as per the country's prioritisation plans for Malaria. Elective switches are not currently permitted for malaria vaccines and the programme implements Product Matching for new introductions; however, exceptional switches are permitted related to affordability (cofinancing, self-financing) subject to meeting specific conditions. Malaria RTS,S pricing is indicative. Actual price will be updated when available following conclusion of ongoing UNICEF tender.

Gavi The Vaccine Alliance



3

Key Insights & Decision-Making

Interpreting Results: Key Indicators

Key indicators supporting scenario review and decision-making

5 KEY INDICATORS

Assess budget fit, explore trade-offs, optimise funding, and review trends

Decision signal

- Within budget
- Over budget

1. **Budget Position**
   Effective Budget comparisons show whether the scenario is within budget, unbalanced, or in deficit across the Guaranteed, Discretionary, and Total budget envelopes.
   The resulting surplus or deficit highlights the extent to which the scenario aligns with the available Vaccine Budget.

2. **Programme Composition & Financing**
   Shows which programmes are prioritised in the scenario, those designated as stand-by activities, the budget category supporting each programme, and the distribution of costs across Gavi support, co-financing, and self-financing.

3. **Programme Design Adjustments**
   Highlights changes made to programme design to align ambitions with available resources, including adjustments to introduction timing, product selection, programme scale, coverage assumptions, and other key parameters.

4. **Budget Adjustments**
   Identifies the financing mechanisms used to improve budget alignment, including self-financing, transfers from Discretionary to Guaranteed funding, and stand-by list designation.

5. **Demand Trends**
   Displays 2026–2027 Decision Letter commitments alongside annual volume projections, providing a view of expected demand and programme trajectory across the strategic period.

Gavi The Vaccine Alliance

Decision Making Flow: Budget Calibration

Does the total scenario cost fit within the Vaccine Budget?

NO → **Identify funding gap**

YES → **PATHWAY 1 · PROCEED**

YES → Proceed with full programme scenario → **FINALISE SCENARIO**

PATHWAY 2 · BUDGET TRANSFER

Can surplus discretionary funds be repurposed for guaranteed programmes?

YES → Transfer discretionary funds to the guaranteed budget → Does the revised scenario fit within the budget?

- YES → **FINALISE SCENARIO**
- NO → Consider Pathway 3 & 4

PATHWAY 3 · STAND-BY LIST

Are there programmes to hold for future funding?

YES → Select stand-by list programmes among new introductions → Does the revised scenario fit within the budget?

- YES → **FINALISE SCENARIO**
- NO → Consider Pathway 4

PATHWAY 4 · SELF-FINANCING

Can the country self-finance one or more programmes?

Select programme(s) for self-financing → Does the revised scenario fit within the budget?

- YES → Discretionary funds remaining?
  - Pathway 1
- NO → Expand self-financing
  - OR → Pathway 3

Stand-by list leads to the prioritisation process if additional Gavi funding becomes available

Gavi The Vaccine Alliance


Interaction of the Guaranteed and Discretionary Budgets

Flexibility in funds within the vaccine budgets depends on programme category and financing options

Vaccine Budgets Policy Guidance

Self-financing guaranteed programmes frees up funds for reallocation across eligible programmes

Discretionary budget surpluses can be used to supplement guaranteed programmes



Gavi The Vaccine Alliance



SUPPORT

For further assistance please contact your:

- SCM/PM
- VFSM focal point
- IF&S focal point


Gavi
The Vaccine Alliance